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Abstract
Objective: Kashin-Beck Disease (KBD) is an endemic, age-related degenerative osteoarthropathy and its cause is
hypothesised to involve Fusarium mycotoxins. This study investigated the Fusarium mycotoxin Nivalenol (NIV) on the
metabolism of bovine articular chondrocytes in vitro.
Design: The effect 0.0–0.5 mg/ml NIV on transcript levels of types I and II collagen, aggrecan, matrix metalloproteinases
(MMPs), a disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) and the tissue inhibitors of MMPs
(TIMPs) was investigated using quantitative PCR. Amounts of sulphated glycosaminoglycans, MMPs and TIMPs were
assessed using the Dimethylmethylene Blue assay, gelatin zymography and reverse gelatin zymography respectively.
Cytoskeletal organisation was analysed using confocal microscopy and cytoskeletal gene and protein levels were measured
by quantitative PCR and Western blot analysis, respectively.
Results: NIV caused a dose-dependent increase in aggrecan transcription with a concomitant retention of sGAG in the cell
lysate. Furthermore, NIV significantly increased MMPs-2, -3 & -9, ADAMTS-4 and -5, and TIMP-2 and -3 transcript levels but
inhibited type I collagen, MMP 1 and TIMP 1 mRNA levels. NIV promoted extensive cytoskeletal network remodelling,
particularly with vimentin where a dose-dependent peri-nuclear aggregation occurred.
Conclusion: NIV exposure to chondrocytes decreased matrix deposition, whilst enhancing selective catabolic enzyme
production, suggesting its potential for induction of cellular catabolism. This NIV-induced extracellular matrix remodelling
may be due to extensive remodelling/disassembly of the cytoskeletal elements. Collectively, these findings support the
hypothesis that trichothecene mycotoxins, and in particular NIV, have the potential to induce matrix catabolism and
propagate the pathogenesis of KBD.
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Introduction
Kashin-Beck Disease (KBD) is an endemic, age-related degen-
erative osteoarthropathy mainly affecting adolescents [1]. Repre-
sentative pathological changes include chondrocyte necrosis in the
hypertrophic layer near the adjacent subchondral bone, and
articular cartilage degeneration leading to secondary osteoarthritis
[2]. This can cause developmental disorders in KBD patients
inducing deformed joints and microsomia.
The aetiology of KBD is unknown although the combined
environmental and nutritional conditions of the endemic area can
induce the disorder [3,4]. Recently, a hypothesis that KBD is
caused by Fusarium mycotoxins on the stored food was proposed
[2]. The fungi produces several trichothecene mycotoxins
including deoxynivalenol (DON), nivalenol (NIV), T-2 toxin and
zearalenone (ZEA), which have all been found in cereal crops from
KBD afflicted areas [5,6].
Previous studies demonstrated that T-2 toxin inhibits aggrecan
and type II collagen synthesis, promotes the production of
interleukin-1 and induces chondrocyte apoptosis, suggesting a
catabolism stimulating effect on articular cartilage [1,7]. NIV
inhibits DNA and protein synthesis, decreases cell proliferation,
alters cell membrane structure, induces cell apoptosis [8] and
promotes the synthesis of inflammatory cytokines [9]. Treatment
of engineered cartilage with NIV was shown to promote
chondrocyte hypertrophy, as evidenced by increased type X
collagen production [10]. However, very few studies characterising
NIV’s effects on articular cartilage metabolism have been
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conducted. Hence, an awareness of how NIV affects articular
chondrocyte metabolism is important if we are to understand the
underlying mechanisms that initiate the development of cartilage
degeneration in KBD. Therefore, the objectives of this study were
to (i) determine the effect of NIV on chondrocyte cell and matrix
metabolism, and (ii) determine whether the metabolic responses
observed could be attributed to alterations in the integrity of the
cytoskeletal elements in response to NIV exposure. Our studies
have shown that NIV decreased matrix deposition, whilst
enhancing the production of selective catabolic enzymes suggest-
ing its potential to induce catabolism in chondrocytes; further-
more, cytoskeletal element organisation was compromised in
response to NIV.
Materials and Methods
All reagents were obtained from Sigma (Poole, UK) unless
otherwise stated and were of analytical grade or above. Culture
medium consisted of Dulbeccos Modified Eagle’s Medium/Hams
F12-glutamax (DMEM/F12-glutamax (1:1); Invitrogen, UK)
supplemented with 100 U/ml penicillin and 100 mg/ml strepto-
mycin (Invitrogen, UK), 50 mg/ml ascorbate-2-phosphate and 1x
insulin-transferrin-sodium selenite unless indicated otherwise.
Isolation of primary chondrocytes
Primary chondrocytes were isolated from the metacarpophalyn-
geal joints of 7-day-old bovine calves (F Drury & Sons Ltd.,
Swindon, U.K.) within 6 hours of slaughter [11]. Chondrocyte
viability and cell number were determined using the Trypan Blue
assay. Cells were seeded at a density of 16106 cells/well in 24-well
plates and stabilised for 48 hours before treatment.
Treatment with Nivalenol
Nivalenol (NIV), dissolved in DMEM, was added to the culture
media at a final concentration of 0.1, 0.2 or 0.5 mg/ml (0.32–
1.6 mM) [2]; cell cultures without NIV served as controls. NIV
levels in KBD patients are unknown; however, concentrations
were selected on the knowledge that NIV has been detected at
584–1780 mg/kg (1.9–5.7 mM) in cereal crops in China [12].
Media was collected after 24 hours and treatments replenished.
Media was again collected at the termination of the experiment
(72 hours); all media was stored at 220uC until analysis.
Analysis of total cell number and cell viability
To investigate whether NIV induced cell death via necrosis,
apoptosis or a reduction in metabolism, two distinct cell viability
assays were performed. Total lactate dehydrogenase (LDH) -
reflecting cell number and LDH levels in the culture media
(reflecting cell death by necrosis) were determined (CytoTox 96
LDH assay, Promega, UK) according to the manufacturer’s
protocol. Cell viability was calculated as previously described [13].
The 3–(4, 5-dimethylthiazol-2-yl)–2,5-diphenyltetrazolium bro-
mide (MTT) assay was used to investigate whether NIV affected
cell metabolism [14].
Analysis of gene expression using quantitative PCR
Total RNA was extracted and cDNA synthesised [15], and
transcriptional levels of markers of chondrocyte matrix metabo-
lism investigated using quantitative PCR (Mx3000P qPCR system)
[11]; primers were designed to the open reading frame of target
genes [13] with Sybr Green detection. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as an internal reference
for normalisation [7,11]. Data are presented as fold-change in
gene expression after normalisation to GAPDH and the untreated
control cDNA samples.
Analysis of Sulphated Glycosaminoglycans
Amounts of sulphated glycosaminoglycans (sGAG) released into
culture media was determined using the Dimethylmethylene blue
(DMMB) assay [16].
Analysis of cytoskeletal element organisation using
confocal microscopy
Cytoskeletal element organisation in chondrocytes was investi-
gated using immunofluorescence with scanning laser confocal
microscopy [13].
Analysis of protein expression using Western
blotting. Cytoskeletal protein expression in chondrocytes treat-
ed with NIV was analysed using Western blotting [11,13]. To
remove error induced by differences in film exposure, a control
sample was run on each gel and used as a standard for
normalisation purposes.
Analysis of activity in gelatinases and tissue Inhibitors of
matrix metalloproteinases
The expression and activity levels of MMPs-2 and 9, and
TIMPs-1, -2 and -3 in culture media were investigated by gelatin
zymography and reverse gelatin zymography, respectively [17].
MMPs or TIMPs standards were loaded onto each gel enabling
comparison across gels. MMP or TIMP levels (densitometric units)
in the unknown samples were normalised to the mean value of the
standards and further normalised to total protein levels (deter-
mined using the BCA assay).
Statistical analysis
Data are presented as mean 695% confidence intervals with
n= 6 wells per experimental parameter using a cell preparation
derived from 5 or 6 animals (N= 5–6). Data reproducibility was
confirmed by repeating the study on two independent cell
preparations. Data was tested for normality (Anderson-Darling
test) and equal distribution; where data was not of Gaussian
distribution, Johnson Transformation was performed. One-way
analysis of variance (ANOVA) followed by the Bonferroni post-hoc
test were performed using Minitab 15.0 software (Minitab Inc,
USA). Statistical analyses were performed on each independent
experiment and representative data reflecting the trends observed
are presented. Differences were considered statistically significant
at p#0.05.
Results
NIV decreased cell viability in chondrocytes
The MTT assay indicated that 0.5 mg/ml NIV was cytotoxic at
both days 1 (14%; p,0.001) and 3 (44%; p,0.001), whereas
0.2 mg/ml NIV only decreased cell viability after 3 days of
treatment (33%: p,0.001; Figure 1A). In contrast, the LDH assay
indicated that NIV was not cytotoxic after 1 day of treatment
(p = 0.236), but 0.5 mg/ml NIV reduced cell viability after 3 days
(18%; p= 0.001; Figure 1B). The results of the gene and protein
expression data were very similar at days 1 and 3, however,
because of the cytotoxicity observed after 3 days, data obtained
from day 1 has been presented for the analysis (with day 3 data
presented in supplementary figures) and any differences between
the two time points noted in the text.
Nivalenol Induces Chondrocyte Catabolism
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NIV altered expression of extracellular matrix
components
Type I collagen mRNA levels decreased in cells treated with 0.2
(200-fold; p,0.001) and 0.5 mg/ml NIV (500-fold; p,0.001)
whereas 0.1 mg/ml NIV had no effect (p = 0.084; Figure 2A). A
sustained 1000-fold reduction in type I collagen transcription was
observed in cells after 3 days of 0.5 mg/ml NIV treatment,
reduction (Figure S1A). Transcript levels of type II collagen were
unaffected after NIV treatment for 1 (Figure 2B) or 3 days (Figure
S1B). In contrast, aggrecan mRNA levels were significantly
increased in cells treated with 0.2 (2.4-fold; p,0.001) and
0.5 mg/ml NIV (2.6-fold; p,0.001) after 1 day (Figure 2C) and
after 3 days of NIV treatment (Figure S1C). sGAG levels
synthesised (cell lysate) or released (culture media) by the cells
were significantly affected by NIV at both days 1 (Figure 2D) and
3 (Figure S1D). Although the amount of sGAG synthesised by the
chondrocytes was unaffected at day 1 (Figure 2D), a concentration
dependent reduction in sGAG release was observed (19–46%
reduction, p,0.001 with increasing NIV concentration). A
concentration dependent reduction in sGAG release was observed
after 3 days of NIV treatment (38–248% reduction, p,0.001 with
increasing NIV concentration) concomitant with increased
amount of sGAG in the cell lysates (1.7-fold; p,0.001, Figure
S1D).
NIV altered expression of ECM degrading enzymes
ADAMTS-4 and -5: a disintegrin and metalloproteinase with
thrombospondin motif-4 (ADAMTS-4) transcripts were not
detected in untreated or cells treated with 0.1 mg/ml NIV for 1
day. However, its transcription was induced in cells treated with
0.2 and 0.5 mg/ml NIV for 1 day (Figure 3A). ADAMTS-5
mRNA levels, detected in all experimental groups (Figure 3B),
were significantly elevated in chondrocytes treated with 0.2 (4.2-
fold; p = 0.03) and 0.5 mg/ml NIV (7.7-fold; p,0.001). Increased
expression levels of ADAMTS-4 and -5 mRNAs were also
observed after 3 days of NIV treatment (Figure S2).
MMPs -1, -2, -3 and -9: MMP-1 mRNA levels were only
significantly reduced in chondrocytes treated with 0.5 mg/ml NIV
(2-fold; p = 0.003) after 1 day of treatment compared with
untreated cells (Figure 4A). In contrast, significantly higher levels
of MMP-2 (5.8-fold; p,0.001); Figure 4B) and MMP-9 mRNA
(1.6-fold; p,0.001: Figure 4D) were observed in chondrocytes
treated with 0.2 mg/ml NIV for 1 day. Increased transcription of
MMP-2 (3.7-fold; p= 0.046; Figure 4B), MMP-3 (1.8-fold;
p = 0.034; Figure 4C) and MMP-9 (1.6-fold; p,0.001; Figure 4D)
was also observed in chondrocytes treated with 0.5 mg/ml NIV for
1 day. Surprisingly, MMP-13 mRNA levels were below the limit of
detection in these samples (data not shown). Transcriptional
differences in MMP levels were observed after 3 days of NIV
treatment, particularly at 0.5 mg/ml, with enhanced MMPs-2, -3
and -9 transcription and reduced MMP-1 levels (Figures S3A–D).
To determine alterations in MMP protein synthesis, levels of
MMP-2 and MMP-9 released into the culture media were
determined by gelatin zymography (Figure 4E). 0.5 mg/ml NIV
significantly reduced pro-MMP 2 levels after 1 day of treatment (2-
fold; p = 0.02), whereas after 3 days, pro-MMP 2 levels were
significantly increased in response to 0.5 mg/ml NIV (1.5-fold;
p = 0.046; Figure S3E). However, pro-MMP 9 and the active
forms of both MMP-2 and -9 were not detected in any of the
experimental groups.
NIV altered TIMP expression in chondrocytes
After 1 day of treatment, NIV did not affect TIMP-1 mRNA
expression (data not shown). In contrast, TIMP-2 mRNA was
reduced in the presence of 0.1 mg/ml NIV (1.5-fold; p= 0.04), but
significantly increased at 0.2 mg/ml (1.8-fold; p,0.001) and
0.5 mg/ml (2-fold; p,0.001; Figure 5A). Similarly, TIMP-3
transcript levels were significantly increased at 0.2 mg/ml (2.5-
fold; p = 0.016) and 0.5 mg/ml (4-fold; p,0.001; Figure 5B).
Furthermore, all three TIMPs were differentially modulated by
NIV treatment after 3 days with significant inhibition of TIMP-1
mRNA and induction of TIMPs-2 and -3 (Figure S4). To
determine alterations in TIMP protein levels, reverse gelatin
zymography was performed (Figure 5). Only 0.5 mg/ml NIV
significantly reduced the amount of TIMP-1 detected in the
culture media after 1 (2-fold; p = 0.0029; Figure 5C) and 3 days of
treatment (2-fold; p = 0.011; Figure S5A). TIMP-2 levels were
more variable but significantly increased in chondrocytes treated
Figure 1. Nivalenol (NIV) decreases chondrocyte viability in a
dose and duration-dependent manner. Chondrocytes cultured as
a high-density monolayer were treated with 0.1 0.2 or 0.5 mg/ml NIV for
1 & 3 days. Cell viability was determined using A. MTT assay, and B.
LDH assay. Untreated cells served as controls and were assigned a
viability of 100%; cell viability after NIV treatment is relative to the
control. Representative data is presented as Mean 695% CI (n = 6) [**
p#0.01, *** p#0.001].
doi:10.1371/journal.pone.0109536.g001
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with 0.2 mg/ml NIV after 1 day (2-fold; p,0.001; Figure 5D);
TIMP-2 induction was transient in nature as levels decreased after
3 days of NIV treatment (Figure S5B). TIMP-3 protein was not
detected in the media from any of the experimental groups.
To determine whether NIV influences the chondrocyte
cytoskeleton, the organisation and expression of b-actin, b-tubulin
and vimentin were investigated.
NIV altered the organisation and expression of actin
filaments in chondrocytes
F-actin filaments are normally cortical in distribution with a ring
of actin localising underneath the plasma membrane in chondro-
cytes (Figure 6A i & ii), but this became disrupted with increasing
concentration of NIV. After 1 day, cortical F-actin was observed in
cells treated with 0.1 mg/ml NIV but punctate F-actin was also
observed in the cytoplasm (Figure 6A iii & iv). F-actin became
increasingly punctate with loss of cortical structure in cells treated
with 0.2 mg/ml NIV (Figure 6A v & vi) and a complete loss of
cortical F-actin and concomitant presence of punctate F-actin
aggregates in the cytoplasm of 0.5 mg/ml NIV treated cells
(Figure 6A vii & viii).
To assess whether F-actin remodelling was organisational or
due to altered expression, b-actin mRNA and protein levels were
quantified. A significant reduction in b-actin transcription was
observed in cells (Figure 6B) treated with 0.2 mg/ml (2.3-fold;
p = 0.01) and 0.5 mg/ml NIV (5.3-fold; p,0.001). Similar effects
on b-actin gene expression were also observed after 3 days of
treatment (Figure S6A). Reduced levels of b-actin protein were
observed in cells treated with 0.5 mg/ml for 1 day, but this did not
reach statistical significance (2-fold; p= 0.1; Figure 6C). However,
significant decreases in b-actin protein levels were observed in
chondrocytes treated, for 3 days, with either 0.2 mg/ml (2-fold;
p = 0.017) or 0.5 mg/ml NIV (3.4-fold; p= 0.001; Figure S6B).
0.1 mg/ml NIV had no effect on the amount of b-actin mRNA or
protein levels.
Figure 2. Differential effects of Nivalenol (NIV) on the expression of extracellular matrix components. Chondrocytes cultured as a high-
density monolayer were treated with 0.1, 0.2 or 0.5 mg/ml NIV for 1 day. Untreated cells served as controls. Expression of A. Type I collagen, B. Type II
collagen, and C. Aggrecan mRNAs were assessed using quantitative PCR. Data were normalised to the housekeeping gene GAPDH and are presented
as fold change relative to the untreated cells. D. Total sGAG released into the culture media and sGAG levels in cell lysates (normalised to cell
number) after NIV treatment for 1 day was determined using the DMMB assay. Representative data is presented as Mean695% CI (n = 6) [* p#0.05, **
p#0.01, *** p#0.001 when compared to untreated cells].
doi:10.1371/journal.pone.0109536.g002
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NIV altered the organisation and expression of b-tubulin
in chondrocytes
Tubulin microtubules are normally distributed as a meshwork
throughout the cytoplasm from the cell membrane to the nucleus
(Figure 7A i & ii). The tubulin network was observed throughout
the cytoplasm, but not as highly organised, in chondrocytes treated
with 0.1 mg/ml NIV. In cells treated with 0.2 mg/ml (Figure 7A v
& vi) and 0.5 mg/ml NIV (Figure 7A vii & viii) the tubulin network
was predominantly cortical with intense staining at the periphery
of the cell.
b-tubulin transcription was significantly reduced in chondro-
cytes treated for 1 day with 0.2 mg/ml (4-fold; p,0.001) or
0.5 mg/ml NIV (2.1-fold; p,0.001; Figure 7B); 0.1 mg/ml NIV
had no effect on b-tubulin transcription. After 3 days, b-tubulin
mRNA levels were further reduced in cells treated with all three
concentrations of NIV in a dose-dependent manner (Figure S7A).
In contrast to the gene expression data, 0.2 mg/ml NIV
significantly increased the amount of b-tubulin detected by
Western blotting (1.5-fold; p = 0.004; Figure 7C); the other NIV
concentrations did not affect the levels of b-tubulin. After 3 days,
the only effect was a subtle reduction in b-tubulin protein levels in
response to 0.5 mg/ml NIV (1.3-fold; p = 0.04; Figure S7B).
NIV induced peri-nuclear aggregation of the vimentin
cytoskeleton in chondrocytes
Vimentin intermediate filaments are normally distributed as a
fine meshwork throughout the cytoplasm of chondrocytes
(Figure 8 i & ii). A loss of vimentin filament organisation,
concomitant with a partial collapse of the network around the
nucleus was observed in cells treated with 0.1 mg/ml NIV
(Figure 8 iii & iv). At the higher NIV concentrations, both
0.2 mg/ml (Figure 8 v & vi) and 0.5 mg/ml (Figure 8 vii & viii)
resulted in a re-distribution of vimentin as evidenced by juxta-
nuclear aggregation. Surprisingly there were no apparent changes
in vimentin transcription or protein amounts over the 3 day period
(data not shown).
Discussion
It has been hypothesised that KBD is caused by Fusarium
mycotoxins which inhibit cell proliferation and promote cell death
[8]; the disease is characterised by chondrocyte necrosis in the
hypertrophic layer near the adjacent subchondral bone and
pathological changes to the articular cartilage [2]. Hence, an
awareness of how NIV affects articular chondrocyte metabolism is
important if we are to understand the underlying mechanisms that
initiate the development of cartilage degeneration in KBD. In this
study, NIV was added to chondrocyte cultures at a final
concentration of 0.1, 0.2 or 0.5 mg/ml (0.32–1.6 mM); although
IC50 values are not known for chondrocytes, it has previously
been demonstrated that NIV has an IC50 value of 1.1 mM and
0.32 mM in 3T3 mouse fibroblasts as detected by BrdU
incorporation and visual inspection, respectively (reviewed in
[18]). Two separate assays i.e. MTT and LDH assay were
performed to assess cell viability after NIV treatment (0.32–
1.6 mM). The MTT assay assesses cellular metabolism based on
the ability of cells to convert the yellow compound MTT to a blue
formazan dye in the mitochondria. In contrast, the LDH assay
assesses cell viability by detecting the amount of LDH released into
the culture medium due to cell lysis. Using the LDH assay, NIV
was cytotoxic at a concentration of 0.5 mg/ml, whereas the MTT
assay indicated that 0.2 and 0.5 mg/ml reduced cellular metab-
olism over the 3 day period. This difference may indicate that
NIV-induced chondrocyte cytotoxicity results from disruption of
metabolism and/or apoptosis as opposed to cell lysis by necrosis as
shown in similar studies with chondrocytes [1,7] and an
erythroleukemia cell line [19]. Although NIV is cytotoxic to
chondrocytes, interestingly, many of the effects identified in this
study related to increased expression levels indicating that NIV-
induced cell death did not promote a general down-regulation of
cell metabolism in the time period covered in this study. NIV is
reported to inhibit protein synthesis in rabbit reticulocytes in vitro
at a concentration of 2.5 mg/ml (Scientific Committee for Food
report: http://ec.europa.eu/food/fs/sc/scf/out74_en.pdf), with
greater toxicity in cell types with high cell proliferation rates, a
feature that is not ordinarily attributed to chondrocytes. There-
fore, we do not believe that the observed cellular responses are
non-specific effects of NIV-induced cytotoxicity.
Figure 3. Nivalenol (NIV) induces ADAMTS-4 and -5 gene
expression. Chondrocytes cultured as a high-density monolayer were
treated with 0.1, 0.2 or 0.5 mg/ml NIV for 1 day. Untreated cells served as
controls. Expression of A. ADAMTS-4 and B. ADAMTS-5 were assessed
using quantitative PCR. Data were normalised to the housekeeping
gene GAPDH and are presented as fold change relative to the untreated
cells [refer to Figure 2 for data analysis and statistical representation].
doi:10.1371/journal.pone.0109536.g003
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Previous studies showed that the Fusarium mycotoxin T-2 toxin
inhibits aggrecan and type II collagen synthesis whilst promoting
the production of inflammatory cytokines (e.g. IL-1) [1,7],
illustrating a pro-degradative cartilage chondrocyte phenotype as
observed in KBD. Therefore, we investigated whether NIV, a
related trichothecene mycotoxin also promoted a catabolic
Figure 5. Differential effects of Nivalenol (NIV) on TIMP expression. Chondrocytes cultured as a high-density monolayer were treated with
0.1, 0.2 or 0.5 mg/ml NIV for 1 day. Untreated cells served as controls. Expression levels of A. TIMP-2 and B. TIMP-3 were assessed using quantitative
PCR. Data were normalised to the housekeeping gene GAPDH and are presented as fold change relative to the untreated cells. Levels of C. TIMP-1
and D. TIMP-2 released into the culture media, after 1 day of NIV treatment, was determined by reverse gelatin zymography; data was normalised to
protein content and presented as fold change relative to the untreated cells [refer to Figure 2 for data analysis and statistical representation].
doi:10.1371/journal.pone.0109536.g005
Figure 4. Nivalenol (NIV) modulates MMP expression. Chondrocytes cultured as a high-density monolayer were treated with 0.1, 0.2 or 0.5 mg/
ml NIV for 1 day. Untreated cells served as controls. Expression of A. MMP-1, B. MMP-2, C. MMP-3 and D. MMP-9 were assessed using quantitative
PCR. Data were normalised to the housekeeping gene GAPDH and are presented as fold change relative to the untreated cells. E. Levels of MMP-2
released into the culture media, after 1 day of NIV treatment, was determined by gelatin zymography; data was normalised to protein content and
presented as fold change relative to the untreated cells [refer to Figure 2 for data analysis and statistical representation].
doi:10.1371/journal.pone.0109536.g004
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Figure 6. Nivalenol (NIV) disassembles the F-actin cytoskeleton and reduces b-actin expression. Chondrocytes cultured as a high-density
monolayer were treated with 0.1, 0.2 or 0.5 mg/ml NIV for 1 day. Untreated cells served as controls. A. F-actin filament organisation as detected using
Alexa488-phalloidin in conjunction with confocal microscopy; nuclei are counterstained with DAPI. Representative serial sections through the middle
of the cell and 3D-reconstructions are presented [scale bar = 2 mm]. B. b-actin mRNA levels were assessed using quantitative PCR. Data were
normalised to the housekeeping gene GAPDH and are presented as fold change relative to the untreated cells. C. b-actin protein levels were
determined by Western blotting (equivalent protein loading) and data presented as fold change relative to the untreated cells [refer to Figure 2 for
data analysis and statistical representation].
doi:10.1371/journal.pone.0109536.g006
Nivalenol Induces Chondrocyte Catabolism
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Figure 7. Nivalenol (NIV) alters the organisation and expression of b-tubulin. Chondrocytes cultured as a high-density monolayer were
treated with 0.1, 0.2 or 0.5 mg/ml NIV for 1 day. Untreated cells served as controls. A. Tubulin organisation as detected using anti-tubulin primary and
TRITC-conjugated secondary antibodies in conjunction with confocal microscopy; nuclei are counterstained with DAPI. Representative serial sections
through the middle of the cell and 3D-reconstructions are presented [scale bar = 2 mm]. B. b-tubulin mRNA levels were assessed using quantitative
PCR. Data were normalised to the housekeeping gene GAPDH and are presented as fold change relative to the untreated cells. C. b-tubulin protein
levels were determined by Western blotting (equivalent protein loading) and data presented as fold change relative to the untreated cells [refer to
Figure 2 for data analysis and statistical representation].
doi:10.1371/journal.pone.0109536.g007
Nivalenol Induces Chondrocyte Catabolism
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chondrocyte phenotype. Interestingly, NIV did not affect type II
collagen transcription, but significantly inhibited type I collagen
gene expression. In a recent study, 3 weeks of NIV treatment
reduced type II collagen and enhanced type X collagen [10]. Type
X collagen is exclusively synthesised by terminally differentiating
chondrocytes i.e. hypertrophic chondrocytes in the growth plate; it
facilitates the process of calcification and therefore has a critical
role to play in matrix mineralisation and endochondral ossifica-
tion. NIV-induced type X collagen expression may be an attempt
at recapitulating endochondral bone formation, and may partly
explain the osteoarthritic phenotype that characterises KBD. In
contrast, NIV treatment elevated aggrecan mRNA levels suggest-
ing that NIV can induce proteoglycan synthesis in chondrocytes,
which is consistent with the increased sGAG levels in cell lysates
over the 3 day treatment period. This agrees with the reported
increase in aggrecan levels in response to NIV treatment [10].
Interestingly, this NIV-induced elevation of sGAG levels in cells,
concomitant with a reduced release into the media, is suggestive of
accumulation of proteoglycan in the cytoplasm. This intra-cellular
accumulation could be attributed to NIV-induced tubulin
reorganisation –a cytoskeletal network which is essential for sGAG
secretion [20,21]. Our results corroborate the NIV study on
engineered cartilage [10] but differ from the T-2 toxin inhibition
of matrix synthesis in human chondrocytes cultured in vitro [1,7],
which may reflect differences in the mycotoxins used or the time
points chosen for analysis in these studies.
The major proteolytic enzymes involved in cartilage catabolism
include the ADAMTSs which primarily degrade aggrecan and the
MMPs which degrade the collagen network and other matrix
proteins. In our study, NIV significantly increased ADAMTS-4
and -5 in a concentration dependent manner with ADAMTS-4
being more sensitive to NIV treatment. It has been shown that
ADAMTS-4, is the major aggrecanase involved in proteoglycan
degradation in human OA cartilage [22–24], even though
ADAMTS-5 has a higher ‘‘aggrecanase’’ activity [25]. Although
we have not ascertained the relative catabolic activities of
ADAMTS-4 and -5, NIV enhances the transcriptional expression
of both enzymes significantly and therefore both would likely
contribute to cartilage matrix degradation, as observed in KBD.
In addition, NIV increased MMP-2, MMP-3 and MMP-9
transcription in chondrocytes, which together, are capable of
digesting ECM components including collagen and aggrecan in
cartilage, and their elevated active protein expression levels are
usually an indicator of catabolism. NIV increased MMP-3
transcription; elevated MMP-3 levels were also reported in
engineered cartilage exposed to NIV for 3 weeks [10]. Previous
studies have shown that MMP-3 is critical to articular cartilage
destruction in OA not only digesting several cartilage ECM
components but also activating pro-MMP 1, -7, -8, -9 and -13
[26]. Previously increased MMP-1 expression was observed [10],
however in our study MMP1 was decreased by NIV treatment;
these opposing effects may reflect the different treatment durations
and culture systems used in these studies. Although MMP-13 is a
primary candidate for cartilage degradation [23,27], we were
unable to detect any significant expression of MMP-13 in this
study.
TIMPs are the native inhibitors of both the ADAMTSs and
MMPs in vivo. NIV significantly decreased expression of TIMP-1
causing an imbalance in the levels of the MMPs and the inducible
TIMP-1 suggesting the potential to stimulate chondrocyte
catabolism. Surprisingly, TIMP-2 gene and protein expression
were elevated after NIV treatment. TIMP-2 is constitutively
expressed in both normal and OA articular chondrocytes [28,29].
TIMP-2 has two different roles: activation of pro MMP-2 and
inhibition of MMPs [30,31]. The overall effect of TIMP-2 is
determined by the ratio between TIMP-2 and MMP-2 [32];
normally TIMP-2 activates MMP-2 promoting catabolism, whilst
excessive TIMP-2 is required to inhibit MMP activities. At the
gene level, NIV stimulated expression of MMP-2 significantly
more than TIMP-2, perhaps shifting the normal inhibitory role to
an MMP-2 activating role promoting ECM catabolism. TIMP-3
transcription was highly responsive to NIV (#4 and 16-fold
increase after 1 and 3 days respectively). TIMP-3 is elevated in
human osteoarthritic cartilage [33]; previous studies have dem-
onstrated that TIMP-3 inhibits sGAG release [34] and is also a
potent inducer of apoptosis [35]. NIV inhibited sGAG release and
induced cell death in a concentration-dependent manner suggest-
ing that the significantly inducible TIMP-3 may facilitate these
effects.
Cytoskeletal elements play crucial roles in cellular metabolism,
migration, division and cell-ECM signalling. Previous studies,
including our own [11] have demonstrated that many of the
phenotypic changes observed in the chondrocytes with NIV
treatment are reminiscent of effects observed upon disruption of
Figure 8. Nivalenol (NIV) induces peri-nuclear aggregation of the vimentin cytoskeleton. Chondrocytes cultured as a high-density
monolayer were treated with 0.1, 0.2 or 0.5 mg/ml NIV for 1 day. Untreated cells served as controls. Vimentin organisation was detected using anti-
vimentin primary and TRITC-conjugated secondary antibodies in conjunction with confocal microscopy; nuclei are counterstained with DAPI.
Representative serial sections through the middle of the cell and 3D-reconstructions are presented [scale bar = 2 mm].
doi:10.1371/journal.pone.0109536.g008
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the cytoskeletal elements indicating an important role for these
networks in maintaining cartilage homeostasis (reviewed in [36]).
As NIV shifted the apparent phenotypic balance towards
catabolism and prevented sGAG secretion into the medium,
analogous to that observed on disruption of the cytoskeletal
elements of chondrocytes [11,21,37], we investigated whether NIV
acts through a similar mechanism. With increasing NIV concen-
tration, vimentin lost its uniform cytoplasmic meshwork forming
juxta-nuclear aggregates, resembling that observed using acryl-
amide to disrupt the vimentin network [11]. Disassembly of the
vimentin network inhibits the production of type II collagen and
aggrecan in cartilage chondrocytes [11] and vimentin knockdown
using siRNA had comparable effects in progenitor stem cells [38].
Therefore, the extensive remodelling of the vimentin network may
contribute to the catabolic phenotype characterised by KBD. The
actin cytoskeleton is critical for maintaining the chondrocyte
phenotype [39,40]. NIV disrupted the normal distribution of actin
in chondrocytes. The increase in punctate cytoplasmic F-actin
resembles the localisation profile observed upon cytochalasin D
treatment which disrupts F-actin formation [41]. NIV also
reduced the levels of b-actin mRNA and protein, which in
concert with the phenotypic shift to the production of catabolic
components is consistent with such a disruption of the actin
network. Remodelling of the tubulin cytoskeleton and a reduction
in the levels of b-tubulin gene and protein, were observed after
NIV treatment. The tubulin microtubular network is pivotal for
intra-cytoplasmic transport and trafficking [11,42]. Loss of
organisation has been shown to adversely affect the synthesis
and secretion of both collagen and proteoglycan in chondrocytes
[21,43–46], demonstrating the importance of an intact microtu-
bule network for cartilage homeostasis. NIV decreased the amount
of sGAG released into the culture medium concomitant with
increased retention in the cell layer; therefore, the loss of a
uniformly distributed tubulin network in NIV treated cells may
have interfered with the cell’s ability to synthesise and secrete the
sGAGs. Whether the alteration in the organisation and/or
expression of these cytoskeletal proteins in chondrocytes are a
direct effect of NIV treatment or are mediated as a secondary
response, the shift to a more catabolic phenotype is consistent with
the effects being mediated through disruption of the chondrocyte
cytoskeleton.
In summary, for the first time, the effects of the mycotoxin NIV,
hypothesised to be involved in the development of KBD, has been
investigated on bovine chondrocyte metabolism in vitro. Our
studies have shown that NIV decreased matrix deposition, whilst
enhancing the production of selective catabolic enzymes e.g.
MMPs-2, -3 and -9 and ADAMTS-4 and -5, suggesting its
potential to induce catabolism in chondrocytes. We hypothesise
that the observed reduction in matrix production is attributed to
the extensive remodelling/disassembly of the cytoskeletal elements
in response to NIV. To date, studies characterising the organisa-
tion of the cytoskeletal elements in the cartilage of KBD sufferers
have not been performed, but this would be interesting and may
elucidate further a mechanism by which this disease leads to
cartilage pathology. However, one needs to be cautious in
extrapolating our in vitro results with the in vivo situation because
the concentration of NIV in the target cells i.e. chondrocytes in
vivo, after exposure to the toxin is unknown. Very few studies have
been conducted in this area, but it was demonstrated that plasma
levels in pigs (oral NIV dosing of 0.05 mg/kg body weight twice
daily) was 3–6 mg/L [47], which is lower than the NIV
concentrations applied to the chondrocytes in our study. It is not
thought that NIV accumulates in the tissues of either humans or
other animals, thus it is likely that the joints, and in particular the
articular chondrocytes do not experience these high concentra-
tions in vivo. However, long term exposure to NIV, even at these
lower concentrations reported by Hedman et al. which are
unlikely to be cytotoxic, could still have detrimental consequences
on chondrocyte metabolism. Therefore, our findings support the
hypothesis that trichothecene mycotoxins, and in particular NIV,
induces matrix catabolism, and furthermore proposes a mecha-
nism by which NIV could propagate the pathogenesis of KBD.
Supporting Information
Figure S1 Differential effects of Nivalenol (NIV) on the
expression of extracellular matrix components. Chon-
drocytes cultured as a high-density monolayer were treated with
0.1, 0.2 or 0.5 mg/ml NIV for 3 days. Untreated cells served as
controls. Expression of A. Type I collagen, B. Type II collagen,
and C. Aggrecan mRNAs were assessed using quantitative PCR.
Data were normalised to the housekeeping gene GAPDH and are
presented as fold change relative to the untreated cells. D. Total
sGAG released into the culture media and sGAG levels in cell
lysates (normalised to cell number) was determined using the
DMMB assay. Representative data is presented as Mean 695%
CI (n= 6) [* p#0.05, ** p#0.01, *** p#0.001 when compared to
untreated cells].
(TIF)
Figure S2 Nivalenol (NIV) induces ADAMTS-4 & 5 gene
expression. Chondrocytes cultured as a high-density monolayer
were treated with 0.1, 0.2 or 0.5 mg/ml NIV for 3 days. Untreated
cells served as controls. Expression of ADAMTS-4 & 5 mRNA
was assessed using quantitative PCR. ADAMTS-4 transcripts were
not detected in untreated cells, however, to allow calculation of
fold change in expression with NIV treatment, an artificial value of
1 was assigned to the cells in which ADAMTS-4 was not detected.
Data were normalised to the housekeeping gene GAPDH and are
presented as fold change relative to the untreated cells [refer to
Figure 1 for data analysis and statistical representation].
(TIF)
Figure S3 Nivalenol (NIV)-induces differential regula-
tion of MMPs expression. Chondrocytes cultured as a high-
density monolayer were treated with 0.1, 0.2 or 0.5 mg/ml NIV for
3 days. Untreated cells served as controls. Expression of A.MMP-
1, B. MMP-2, C. MMP-3, and D. MMP-9 were assessed using
quantitative PCR. Data were normalised to the housekeeping gene
GAPDH and are presented as fold change relative to the untreated
cells. E. Levels of MMP-2 released into the culture media was
determined by gelatin zymography, data normalised to protein
content and presented as fold change relative to the untreated cells
[refer to Figure 1 for data analysis and statistical representation].
(TIF)
Figure S4 Nivalenol (NIV)-induces differential regula-
tion of TIMPs transcription. Chondrocytes cultured as a
high-density monolayer were treated with 0.1, 0.2 or 0.5 mg/ml
NIV for 3 days. Untreated cells served as controls. Expression of
A. TIMP-1, B. TIMP-2, and C. TIMP-3 were assessed using
quantitative PCR. Data were normalised to the housekeeping gene
GAPDH and are presented as fold change relative to the untreated
cells [refer to Figure 1 for data analysis and statistical represen-
tation].
(TIF)
Figure S5 Nivalenol (NIV)-induces differential regula-
tion of TIMPs levels. Chondrocytes cultured as a high-density
monolayer were treated with 0.1, 0.2 or 0.5 mg/ml NIV for 3 days.
Untreated cells served as controls. Levels of A. TIMP-1 and B.
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TIMP-2 released into the culture media were determined by
reverse gelatin zymography, data normalised to protein content
and presented as fold change relative to the untreated cells [refer
to Figure 1 for data analysis and statistical representation].
(TIF)
Figure S6 Nivalenol (NIV) disassembles the F-actin
cytoskeleton and reduces b-actin expression. Chondro-
cytes cultured as a high-density monolayer were treated with 0.1,
0.2 or 0.5 mg/ml NIV for 3 days. Untreated cells served as
controls. A. b-actin mRNA levels were assessed using quantitative
PCR. Data were normalised to the housekeeping gene GAPDH
and are presented as fold change relative to the untreated cells. B.
b-actin protein levels were determined by Western blotting
(equivalent protein loading) and data presented as fold change
relative to the untreated cells [refer to Figure 1 for data analysis
and statistical representation].
(TIF)
Figure S7 Nivalenol (NIV) alters the organisation and
expression of b-tubulin. Chondrocytes cultured as a high-
density monolayer were treated with 0.1, 0.2 or 0.5 mg/ml NIV for
3 days. Untreated cells served as controls. A. b-tubulin mRNA
levels were assessed using quantitative PCR. Data were normalised
to the housekeeping gene GAPDH and are presented as fold
change relative to the untreated cells. B. b-tubulin protein levels
were determined by Western blotting (equivalent protein loading)
and data presented as fold change relative to the untreated cells
[refer to Figure 1 for data analysis and statistical representation].
(TIF)
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